Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05260957 · ClinicalTrials.gov registry record · Phase 2
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
A Phase 2 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma, sponsored by Lazaros Lekakis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05260957 is a Phase 2 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma that is actively recruiting participants, run by Lazaros Lekakis. The registered enrollment target is 22 participants, below the 95-participant average among 17 other Refractory Non-Hodgkin Lymphoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05260957, a Phase 2 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Lazaros Lekakis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to test if a combination treatment of chimeric antigen receptor (CAR) T-cell therapy, Mosunetuzumab, and Polatuzumab Vedotin will result in tumor reduction.
Conditions Studied
Interventions
- DRUG Mosunetuzumab
- DRUG Polatuzumab
- BIOLOGICAL CAR-T Cell Therapy
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05260957
The ClinicalTrials.gov registry entry for NCT05260957 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 17 other Refractory Non-Hodgkin Lymphoma trials with a reported enrollment target (77% lower). The listed sponsor is Lazaros Lekakis, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Refractory Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Mosunetuzumab is the first listed.
NCT05260957 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05260957 about?
NCT05260957 is a clinical study titled "CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).". The purpose of this research study is to test if a combination treatment of chimeric antigen receptor (CAR) T-cell therapy, Mosunetuzumab, and Polatuzumab Vedotin will result in tumor reduction.
What is the current status of trial NCT05260957?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2022-12-14. Estimated completion is 2028-12-31.
What conditions does trial NCT05260957 study?
This clinical trial studies the following conditions: Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05260957?
The interventions under investigation include: Mosunetuzumab (DRUG), Polatuzumab (DRUG), CAR-T Cell Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT05260957?
This trial is sponsored by Lazaros Lekakis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05260957 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.